MDM2 gene promoter polymorphisms and risk of lung cancer: A case-control analysis

Carcinogenesis

Volumn 27, Issue 10, 2006, Pages 2028-2033

  Li, Guojun ^a   Zhai, Xiaodong ^a   Zhang, Zhengdong ^a   Chamberlain, Robert M ^a   Spitz, Margaret R ^a   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GUANINE; PROTEIN MDM2; PROTEIN P53; TYROSINE;

ADULT; AGE; AGED; ALLELE; APOPTOSIS; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CELL CYCLE REGULATION; CELL GROWTH; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA REPAIR; ETHNIC DIFFERENCE; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; HUMAN CELL; HYPOTHESIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 33749546905     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl047     Document Type: Article

References (33)

1. Spitz,M.R., Wei,Q., Dong,Q., Amos,C.I. and Wu,X. (2003) Genetic susceptibility to lung cancer: The role of DNA damage and repair. Cancer Epidemiol. Biomarkers Prev., 12, 689-698.
2. Wei,Q., Cheng,L., Amos,C.I., Wang,L.E., Guo,Z., Hong,W.K. and Spitz,M.R. (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J. Natl. Cancer Inst., 92, 1764-1772.
3. Vonlanthen,S., Heighway,J., Kappeler,A., Altermatt,H.J., Bomer,M.M. and Betticher,D.C. (2000) p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. Intl. J. Oncol., 16, 951-957.
4. Wang,L.E., Cheng,L., Spitz,M.R. and Wei,Q. (2003) Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer, 42, 1-8.
5. Vogelstein,B., Lane,D. and Levine,A.J. (2000) Surfing the p53 network. Nature, 408, 307-310.
6. Woods,D.B. and Vousden,K.H. (2001) Regulation of p53 function. Exp. Cell Res., 264, 56-66.
7. Yang,A., Walker,N., Bronson,R. et al. (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature, 404, 99-103.
8. Wang,X.Q., Ongkeko,W.M., Lau,A.W., Leung,K.M. and Poon,R.Y. (2001) A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res., 61, 1598-1603.
9. Momand,J. and Zambetti,G.P. (1997) Mdm-2: 'big brothe' of p53. J. Cell. Biochem., 64, 343-352.
10. Freedman,D.A., Wu,L. and Levine,A.J. (1999) Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci., 55, 96-107.
11. Martin,K., Trouche,D., Hagemeier,C., Sorensen,T.S., La Thangue,N.B. and Kouzarides,T. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375, 691-694.
12. Xiao,Z.X., Chen,J., Levine,A.J., Modjtahedi,N., Xing,J., Sellers,W.R. and Livingston,D.M. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 375, 694-698.
13. Brown,D.R., Thomas,C.A. and Deb,S.P. (1998) The human oncoprotein MDM2 arrests the cell cycle: Elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17, 2513-2525.
14. Oliner,J.D., Kinzler,K.W., Meltzer,P.S., George,D.L. and Vogelstein,B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83.
15. Gorgoulis,V.G., Zacharatos,P., Kotsinas,A. et al. (2000) Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Mol. Med., 6, 208-237.
16. Eymin,B., Gazzeri,S., Brambilla,C. and Brambilla,E. (2002) Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene, 21, 2750-2761.
17. Rasidakis,A., Orphanidou,D., Kalomenidis,J., Papamichalis,G., Toumbis,M., Lambaditis,J., Sacharidou,A., Papastamatiou,H. and Jordanoglou,J. (1998) Expression of mdm-2 protein in neoplastic, preneoplastic, and normal bronchial mucosa specimens: Comparative study with p53 expression. Hybridoma, 17, 339-345.
18. Freedman,D.A. and Levine,A.J. (1999) Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res., 59, 1-7.
19. National Institute of Environmental Health Sciences, Environmental Genome Projects. NIEHS SNPS, Dec. 2004.
20. Bond,G.L., Hu,W., Bond,E.E. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
21. Li,G., Wang,L.E., Chamberlain,R.M., Amos,C.I., Spitz,M.R. and Wei,Q. (2004) p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res., 64, 6863-6866.
22. Dobbelstein,M., Wienzek,S., Konig,C. and Roth,J. (1999) Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene, 18, 2101-2106.
23. Zhang,Y., Xiong,Y. and Yarbrough,W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92, 725-734.
24. Powell,B.L., van Staveren,I.L., Roosken,P., Grieu,F., Berns,E.M. and Iacopetta,B. (2002) Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis, 23, 311-315.
25. Rebbeck,T.R., Spitz,M. and Wu,X. (2004) Assessing the function of genetic variants in candidate gene association studies. Nat. Rev. Genet., 5, 589-597.
26. Deb,S.P. (2003) Cell cycle regulatory functions of the human oncoprotein MDM2. Mol. Cancer Res., 1, 1009-1016.
27. Ma,H., Hu,Z., Zhai,X. et al. (2005) Polymorphisms in the MDM2 promoter and risk of breast cancer: A case-control analysis in a Chinese population. Cancer Lett. Nov 7; [Epub ahead of print].
28. Campbell,I.G., Eccles,D.M. and Choong,D.Y.H. (2005) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. Oct. 17; [Epub ahead of print].
29. Alhopuro,P., Ylisaukko-oja,S.K., Koskinen,W.J. et al. (2005) The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J. Med. Genet., 42, 694-698.
30. Sotamaa,K., Liyanarachchi,S., Mecklin,J.P., Heikki Järvinen,H., Aaltonen,L.A., Päivi Peltomäki,P. and Chapelle,A. (2005) p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin. Cancer Res., 1, 6840-6844.
31. Zhang,X., Miao,X., Guo,Y., Tan,W., Zhou,Y., Sun,T., Wang,Y. and Lin,D. (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat., 27, 110-117.
32. Hu,Z., Miao,X., Ma,H., Tan,W., Wang,X., Lu,D., Wei,Q., Lin,D. and Shen,H. (2005) Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int. J. Cancer, 114, 455-460.
33. Deutsch-Wenzel,R.P., Brune,H., Grimmer,G., Dettbarn,G. and Misfeld,J. (1983) Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J. Natl. Cancer Inst., 71, 539-544.